Genomic markers for neuroblastoma risk estimation: superseding tumor stage, age and MYCN?

ISSN： 1752-0363

Source： Biomarkers in Medicine, Vol.7, Iss.6, 2013-12, pp. : 905-908

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Detection of MYCN Amplification and Chromosome 1p36 Loss in Neuroblastoma by cDNA Microarray Comparative Genomic Hybridization

By Paola Scaruffi Stefano Parodi

Molecular Diagnosis, Vol. 8, Iss. 2, 2004-01 ,pp. : 93-100

Adis International

Access to resources Recommend Favorite

Use of genomic markers to risk stratify men with prostate cancer

TRENDS IN UROLOGY AND MEN'S HEALTH, Vol. 6, Iss. 3, 2015-03 ,pp. : 36-39

John Wiley & Sons Inc

Access to resources Recommend Favorite

Striking dichotomy in outcome of MYCN‐amplified neuroblastoma in the contemporary era

CANCER, Vol. 120, Iss. 13, 2014-07 ,pp. : 2050-2059

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of plasma 3,4-dihydroxyphenylacetic acid (DOPAC) and plasma 3,4-dihydroxyphenylalanine (DOPA) as tumor markers in children with neuroblastoma

By Eldrup E. Clausen N. Scherling B. Schmiegelow K.

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 61, Iss. 6, 2001-09 ,pp. : 479-490

Informa Healthcare

Access to resources Recommend Favorite

Pediatric ovarian neoplastic tumors: incidence, age at presentation, tumor markers and outcome

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, Vol. 94, Iss. 4, 2015-04 ,pp. : 425-429

John Wiley & Sons Inc

Access to resources Recommend Favorite